Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users

NCT01785043 on ClinicalTrials.gov · last registry update 2015-09-15

A small phase 4 — 13 participants, against a typical 75. The sponsor logged completion for March 2014. Primary outcome, as filed: Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Anna Cruceta
Sponsor type: Other
Enrollment: 13
Started: 2013-03
Primary completion: 2014-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.

Conditions studied

DIABETES Mellitus Type 2 Not Well Controlled

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.